Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 10/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5547046 | 0.94 | GSK3B (0.42) | BRD4CNR2CNR1GSK3BL3MBTL1 | |
| SCHEMBL5548068 | 0.90 | FEN1 (0.37) | BRD4FEN1CNR2CNR1L3MBTL1 | |
| SCHEMBL5546723 | 0.90 | L3MBTL1 (0.38) | BRD4FEN1CNR2CNR1GSK3B | |
| SCHEMBL5540584 | 0.86 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL5540750 | 0.84 | L3MBTL1 (0.41) | CNR2CNR1GSK3BL3MBTL1TLR2 | |
| SCHEMBL5545522 | 0.84 | RXFP1 (0.41) | FEN1CNR2CNR1L3MBTL1HIF1A | |
| SCHEMBL5540555 | 0.84 | HIF1A (0.41) | CNR2CNR1GSK3BL3MBTL1TLR2 | |
| SCHEMBL5540566 | 0.83 | CNR2 (0.43) | CNR2CNR1GSK3BL3MBTL1TLR2 | |
| SCHEMBL5545339 | 0.83 | HIF1A (0.41) | CNR2CNR1GSK3BL3MBTL1TLR2 | |
| SCHEMBL5545322 | 0.83 | CYP2C19 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | BCDIN3D, DUT, SAMHD1 | BRD4 36/4885FEN1 821/4885CNR2 3954/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | BRD4 223/4885FEN1 436/4885CNR2 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.